Microbiological profile of patients treated for postoperative peritonitis: temporal trends 1999-2019.
Adequate empirical therapy
Empirical antibiotic therapy
Multidrug-resistant bacteria
Optimal empirical therapy
Postoperative peritonitis
Journal
World journal of emergency surgery : WJES
ISSN: 1749-7922
Titre abrégé: World J Emerg Surg
Pays: England
ID NLM: 101266603
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
20
11
2023
accepted:
08
12
2023
medline:
20
12
2023
pubmed:
20
12
2023
entrez:
20
12
2023
Statut:
epublish
Résumé
Temporal changes in the microbiological resistance profile have been reported in several life-threatening infections. However, no data have ever assessed this issue in postoperative peritonitis (POP). Our purpose was to assess the rate of multidrug-resistant organisms (MDROs) in POP over a two-decade period and to analyse their influence on the adequacy of empirical antibiotic therapy (EAT). This retrospective monocentric analysis (1999-2019) addressed the changes over time in microbiologic data, including the emergence of MDROs and the adequacy of EAT for all intensive care unit adult patients treated for POP. The in vitro activities of 10 antibiotics were assessed to determine the most adequate EAT in the largest number of cases among 17 antibiotic regimens in patients with/without MDRO isolates. Our primary endpoint was to determine the frequency of MDRO and their temporal changes. Our second endpoint assessed the impact of MDROs on the adequacy of EAT per patient and their temporal changes based on susceptibility testing. In this analysis, the subgroup of patients with MDRO was compared with the subgroup of patients free of MDRO. A total of 1,318 microorganisms were cultured from 422 patients, including 188 (45%) patients harbouring MDROs. The growing proportions of MDR Enterobacterales were observed over time (p = 0.016), including ESBL-producing strains (p = 0.0013), mainly related to Klebsiella spp (p < 0.001). Adequacy of EAT was achieved in 305 (73%) patients. Decreased adequacy rates were observed when MDROs were cultured [p = 0.0001 vs. MDRO-free patients]. Over the study period, decreased adequacy rates were reported for patients receiving piperacillin/tazobactam in monotherapy or combined with vancomycin and imipenem/cilastatin combined with vancomycin (p < 0.01 in the three cases). In patients with MDROs, the combination of imipenem/cilastatin + vancomycin + amikacin or ciprofloxacin reached the highest adequacy rates (95% and 91%, respectively) and remained unchanged over time. We observed high proportions of MDRO in patients treated for POP associated with increasing proportions of MDR Enterobacterales over time. High adequacy rates were only achieved in antibiotic combinations involving carbapenems and vancomycin, while piperacillin/tazobactam is no longer a drug of choice for EAT in POP in infections involving MDRO.
Sections du résumé
BACKGROUND
BACKGROUND
Temporal changes in the microbiological resistance profile have been reported in several life-threatening infections. However, no data have ever assessed this issue in postoperative peritonitis (POP). Our purpose was to assess the rate of multidrug-resistant organisms (MDROs) in POP over a two-decade period and to analyse their influence on the adequacy of empirical antibiotic therapy (EAT).
METHODS
METHODS
This retrospective monocentric analysis (1999-2019) addressed the changes over time in microbiologic data, including the emergence of MDROs and the adequacy of EAT for all intensive care unit adult patients treated for POP. The in vitro activities of 10 antibiotics were assessed to determine the most adequate EAT in the largest number of cases among 17 antibiotic regimens in patients with/without MDRO isolates. Our primary endpoint was to determine the frequency of MDRO and their temporal changes. Our second endpoint assessed the impact of MDROs on the adequacy of EAT per patient and their temporal changes based on susceptibility testing. In this analysis, the subgroup of patients with MDRO was compared with the subgroup of patients free of MDRO.
RESULTS
RESULTS
A total of 1,318 microorganisms were cultured from 422 patients, including 188 (45%) patients harbouring MDROs. The growing proportions of MDR Enterobacterales were observed over time (p = 0.016), including ESBL-producing strains (p = 0.0013), mainly related to Klebsiella spp (p < 0.001). Adequacy of EAT was achieved in 305 (73%) patients. Decreased adequacy rates were observed when MDROs were cultured [p = 0.0001 vs. MDRO-free patients]. Over the study period, decreased adequacy rates were reported for patients receiving piperacillin/tazobactam in monotherapy or combined with vancomycin and imipenem/cilastatin combined with vancomycin (p < 0.01 in the three cases). In patients with MDROs, the combination of imipenem/cilastatin + vancomycin + amikacin or ciprofloxacin reached the highest adequacy rates (95% and 91%, respectively) and remained unchanged over time.
CONCLUSIONS
CONCLUSIONS
We observed high proportions of MDRO in patients treated for POP associated with increasing proportions of MDR Enterobacterales over time. High adequacy rates were only achieved in antibiotic combinations involving carbapenems and vancomycin, while piperacillin/tazobactam is no longer a drug of choice for EAT in POP in infections involving MDRO.
Identifiants
pubmed: 38115142
doi: 10.1186/s13017-023-00528-1
pii: 10.1186/s13017-023-00528-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Informations de copyright
© 2023. The Author(s).
Références
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensiv Care Med. 2021;47:1181–247.
doi: 10.1007/s00134-021-06506-y
Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med. 2004;32:S513–26.
doi: 10.1097/01.CCM.0000143119.41916.5D
pubmed: 15542959
Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323:1478–87.
doi: 10.1001/jama.2020.2717
pubmed: 32207816
pmcid: 7093816
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55.
doi: 10.1016/S0140-6736(21)02724-0
Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect. 2017;18:1–76.
doi: 10.1089/sur.2016.261
Sartelli M, Catena F, Abu-Zidan FM, Ansaloni L, Biffl WL, Boermeester MA, et al. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World J Emerg Surg. 2017;12:22.
doi: 10.1186/s13017-017-0132-7
pubmed: 28484510
pmcid: 5418731
Montravers P, Dupont H, Leone M, Constantin JM, Mertes PM, Laterre PF, et al. Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med. 2015;34:117–30.
doi: 10.1016/j.accpm.2015.03.005
pubmed: 25922057
Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133–64.
doi: 10.1086/649554
pubmed: 20034345
Cavallazzi R, Wiemken T, Arnold FW, Luna CM, Bordon J, Kelley R, et al. Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. Respir Med. 2015;109:743–50.
doi: 10.1016/j.rmed.2015.04.007
pubmed: 25956021
Metersky ML, Wang Y, Klompas M, Eckenrode S, Mathew J, Krumholz HM. Temporal trends in postoperative and ventilator-associated pneumonia in the United States. Infect Control Hosp Epidemiol. 2023;44:1247–54.
doi: 10.1017/ice.2022.264
pubmed: 36326283
Tsou PY, Yo CH, Hsein YC, Yungtum G, Hsu WT, Chung JY, et al. Temporal trends in the microbiological characteristics of sepsis in the united states: a population based study. J Intensiv Care Med. 2022;37:936–45.
doi: 10.1177/08850666211053778
Launey Y, Duteurtre B, Larmet R, Nesseler N, Tawa A, Mallédant Y, et al. Risk factors for mortality in postoperative peritonitis in critically ill patients. World J Crit Care Med. 2017;6:48–55.
doi: 10.5492/wjccm.v6.i1.48
pubmed: 28224107
pmcid: 5295169
Blot S, Antonelli M, Arvaniti K, Blot K, Creagh-Brown B, de Lange D, et al. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project. Intensiv Care Med. 2019;45:1703–17.
doi: 10.1007/s00134-019-05819-3
Augustin P, Kermarrec N, Muller-Serieys C, Lasocki S, Chosidow D, Marmuse JP, et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care. 2010;14:R20.
doi: 10.1186/cc8877
pubmed: 20156360
pmcid: 2875535
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.
doi: 10.1016/j.jclinepi.2007.11.008
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPSII) based on a European-North American multicenter study. JAMA. 1993;270:2957–68.
doi: 10.1001/jama.1993.03510240069035
pubmed: 8254858
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensiv Care Med. 1996;22:707–10.
doi: 10.1007/BF01709751
Société Française de Microbiologie. Comité de l’antibiogramme de la Société Française de Microbiologie - Recommandations 2023 V.1.0 Juin Accessed July 3rd 2023 from https://www.sfm-microbiologie.org/wp-content/uploads/2023/06/CASFM2023_V1.0.pdf
European Committee on Antimicrobial Susceptibility Testing. (EUCAST) European Society of Clinical Microbiology and Infectious Diseases. Clinical breakpoints and dosing of antibiotics. Accessed Sept 5 2022 from https://www.eucast.org/clinical_breakpoints
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
doi: 10.1111/j.1469-0691.2011.03570.x
pubmed: 21793988
Hernán MA. Causal analyses of existing databases: no power calculations required. J Clin Epidemiol. 2022;144:203–5.
doi: 10.1016/j.jclinepi.2021.08.028
pubmed: 34461211
Friedli O, Völlmy I, Schrenzel J, Harbarth S, Kronenberg A. Retrospective data analysis for definition of multidrug resistance in gram-negative bacteria - a consensus proposal. Swiss Med Wkly. 2022;152:w30195.
doi: 10.4414/SMW.2022.w30195
pubmed: 35816628
Wolfensberger A, Kuster SP, Marchesi M, Zbinden R, Hombach M. The effect of varying multidrug-resistence (MDR) definitions on rates of MDR gram-negative rods. Antimicrob Resist Infect Control. 2019;8:193.
doi: 10.1186/s13756-019-0614-3
pubmed: 31798839
pmcid: 6883537
Grotelueschen R, Luetgehetmann M, Erbes J, Heidelmann LM, Grupp K, Karstens K, et al. Microbial findings, sensitivity and outcome in patients with postoperative peritonitis a retrospective cohort study. Int J Surg. 2019;70:63–9.
doi: 10.1016/j.ijsu.2019.08.020
pubmed: 31437641
Seguin P, Fedun Y, Laviolle B, Nesseler N, Donnio PY, Malledant Y. Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother. 2010;65:342–6.
doi: 10.1093/jac/dkp439
pubmed: 20008043
Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann C, Goretzki PE, et al. The microbiology of postoperative peritonitis. Clin Infect Dis. 2001;33:1513–9.
doi: 10.1086/323333
pubmed: 11568851
Boussion K, Zappella N, Grall N, Ribeiro-Parenti L, Papin G, Montravers P. Epidemiology, clinical relevance and prognosis of staphylococci in hospital-acquired postoperative intra-abdominal infections: an observational study in intensive care unit. Sci Rep. 2021;11:5884.
doi: 10.1038/s41598-021-85443-8
pubmed: 33723332
pmcid: 7960962
Arnaud I, Maugat S, Jarlier V, Astagneau P. Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013. Euro Surveill. 2015;20:36.
doi: 10.2807/1560-7917.ES.2015.20.36.30014
Bonnet R, Dortet L, Jeannot K, Cattoir V. Centre National de Référence de la Résistance aux Antibiotiques. Bilan activité CNR 2017–2021. Accessed July 3
De Pascale G, Carelli S, Vallecoccia MS, Cutuli SL, Taccheri T, Montini L, et al. Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients. J Crit Care. 2019;50:169–76.
doi: 10.1016/j.jcrc.2018.12.001
pubmed: 30553184
Vogelaers D, De Bels D, Forêt F, Cran S, Gilbert E, Schoonheydt K, et al. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates–a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents. 2010;35:375–81.
doi: 10.1016/j.ijantimicag.2009.11.015
pubmed: 20122817
Ciesielczuk H, Wilks M, Castelain S, Choquet M, Morotti M, Pluquet E, et al. Multicenter performance evaluation of the Unyvero IAI cartridge for detection of intra-abdominal infections. Eur J Clin Microbiol Infect Dis. 2018;37:2107–15.
doi: 10.1007/s10096-018-3345-0
pubmed: 30094522
Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med. 1998;338:232–8.
doi: 10.1056/NEJM199801223380406
pubmed: 9435330
Nachtigall I, Tafelski S, Deja M, Halle E, Grebe MC, Tamarkin A, et al. Long-term effect of computer-assisted decision support for antibiotic treatment in critically ill patients: a prospective “before/after” cohort study. BMJ Open. 2014;4:e005370.
doi: 10.1136/bmjopen-2014-005370
pubmed: 25534209
pmcid: 4275685
De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, et al. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensiv Care Med. 2014;40:1340–51.
doi: 10.1007/s00134-014-3403-8
Montravers P, Dufour G, Guglielminotti J, Desmard M, Muller C, Houissa H, et al. Dynamic changes of microbial flora and therapeutic consequences in persistent peritonitis. Crit Care. 2015;19:70.
doi: 10.1186/s13054-015-0789-9
pubmed: 25887649
pmcid: 4354758